Atwater Malick’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.26M | Sell |
29,557
-759
| -3% | -$149K | 1.36% | 17 |
|
|
2026
Q1 | $5.94M | Sell |
30,316
-5,017
| -14% | -$975K | 1.6% | 17 |
|
|
2025
Q4 | $6.13M | Sell |
35,333
-7,609
| -18% | -$1.39M | 1.69% | 17 |
|
|
2025
Q3 | $8.18M | Sell |
42,942
-13,724
| -24% | -$2.44M | 2.38% | 15 |
|
|
2025
Q2 | $10.2M | Buy |
56,666
+18
| +0% | +$3.13K | 3.22% | 13 |
|
|
2025
Q1 | $9.58M | Buy |
56,648
+1,512
| +3% | +$248K | 3.24% | 14 |
|
|
2024
Q4 | $8.32M | Sell |
55,136
-473
| -0.9% | -$73.6K | 2.79% | 14 |
|
|
2024
Q3 | $8.63M | Buy |
55,609
+670
| +1% | +$100K | 2.78% | 16 |
|
|
2024
Q2 | $7.52M | Buy |
54,939
+190
| +0.3% | +$26K | 2.59% | 17 |
|
|
2024
Q1 | $7.29M | Buy |
54,749
+779
| +1% | +$101K | 2.57% | 19 |
|
|
2023
Q4 | $7.44M | Buy |
53,970
+1,244
| +2% | +$164K | 2.92% | 16 |
|
|
2023
Q3 | $6.43M | Buy |
52,726
+634
| +1% | +$84.5K | 2.83% | 16 |
|
|
2023
Q2 | $7.32M | Buy |
52,092
+1,715
| +3% | +$236K | 3.13% | 16 |
|
|
2023
Q1 | $7.13M | Buy |
50,377
+734
| +1% | +$105K | 3.34% | 15 |
|
|
2022
Q4 | $7.77M | Buy |
49,643
+845
| +2% | +$121K | 3.83% | 14 |
|
|
2022
Q3 | $5.99M | Buy |
48,798
+1,264
| +3% | +$166K | 3.35% | 18 |
|
|
2022
Q2 | $6.32M | Buy |
47,534
+1,110
| +2% | +$151K | 3.33% | 16 |
|
|
2022
Q1 | $6.35M | Buy |
46,424
+2,342
| +5% | +$326K | 3.07% | 20 |
|
|
2021
Q4 | $7.63M | Buy |
44,082
+706
| +2% | +$107K | 3.54% | 12 |
|
|
2021
Q3 | $6.3M | Buy |
43,376
+977
| +2% | +$143K | 3.33% | 14 |
|
|
2021
Q2 | $5.59M | Buy |
42,399
+2,944
| +7% | +$385K | 3.09% | 19 |
|
|
2021
Q1 | $5.06M | Sell |
39,455
-2,081
| -5% | -$256K | 3.11% | 19 |
|
|
2020
Q4 | $4.95M | Buy |
41,536
+395
| +1% | +$48.2K | 3.11% | 18 |
|
|
2020
Q3 | $4.71M | Buy |
41,141
+745
| +2% | +$88K | 3.3% | 16 |
|
|
2020
Q2 | $4.6M | Buy |
40,396
+1,831
| +5% | +$194K | 3.62% | 13 |
|
|
2020
Q1 | $3.1M | Buy |
38,565
+2,517
| +7% | +$261K | 2.97% | 21 |
|
|
2019
Q4 | $3.85M | Buy |
36,048
+1,399
| +4% | +$146K | 3.06% | 22 |
|
|
2019
Q3 | $3.71M | Buy |
34,649
+1,575
| +5% | +$162K | 3.11% | 21 |
|
|
2019
Q2 | $3.37M | Buy |
33,074
+894
| +3% | +$85.9K | 3.09% | 21 |
|
|
2019
Q1 | $2.89M | Buy |
32,180
+3,447
| +12% | +$299K | 2.83% | 22 |
|
|
2018
Q4 | $2.39M | Buy |
+28,733
| New | +$2.69M | 2.68% | 24 |
|
Other funds holding DGX
EIG
Atwater Malick's DGX Position: Q2 2026 in Review
Atwater Malick reduced its Quest Diagnostics (DGX) stake by 2.5% in Q2 2026, selling an estimated $149K and leaving 29,557 shares worth $6.26M. The position accounts for 1.36% of the portfolio, ranked #17.
Atwater Malick first reported a position in DGX in Q4 2018 and has held it in 31 quarters since. The position peaked at $10.2M in Q2 2025. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Atwater Malick held 29,557 shares of Quest Diagnostics worth $6.26M as of Q2 2026.
- Atwater Malick sold 759 Quest Diagnostics shares in Q2 2026, an estimated $149K.
- Quest Diagnostics made up 1.36% of Atwater Malick's portfolio in Q2 2026, its #17 holding.
- Atwater Malick first reported a position in Quest Diagnostics in Q4 2018 and has held it in 31 quarters since.
- Atwater Malick's Quest Diagnostics position peaked at $10.2M in Q2 2025.
- 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Atwater Malick's 13F filing for Q2 2026, filed 27 Jul 2026.